Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ALNY logo ALNY
Upturn stock ratingUpturn stock rating
ALNY logo

Alnylam Pharmaceuticals Inc (ALNY)

Upturn stock ratingUpturn stock rating
$322.83
Last Close (24-hour delay)
Profit since last BUY16.73%
upturn advisory
Consider higher Upturn Star rating
BUY since 36 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: ALNY (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Number of Analysts

rating

33 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.

Year Target Price $320.62

Year Target Price $320.62

Analyst’s Price TargetsFor last 52 week
$320.62Target price
Low$205.87
Current$322.83
high$326.03

Analysis of Past Performance

Type Stock
Historic Profit 5.31%
Avg. Invested days 24
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 42.09B USD
Price to earnings Ratio -
1Y Target Price 323.57
Price to earnings Ratio -
1Y Target Price 323.57
Volume (30-day avg) -
Beta 0.21
52 Weeks Range 205.87 - 326.03
Updated Date 06/29/2025
52 Weeks Range 205.87 - 326.03
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.1

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -11.49%
Operating Margin (TTM) 3.04%

Management Effectiveness

Return on Assets (TTM) -1.79%
Return on Equity (TTM) -1500.66%

Valuation

Trailing PE -
Forward PE 2000
Enterprise Value 40786170822
Price to Sales(TTM) 17.93
Enterprise Value 40786170822
Price to Sales(TTM) 17.93
Enterprise Value to Revenue 17.37
Enterprise Value to EBITDA 204.85
Shares Outstanding 130388000
Shares Floating 125463623
Shares Outstanding 130388000
Shares Floating 125463623
Percent Insiders 3.83
Percent Institutions 97.5

Analyst Ratings

Rating 4
Target Price 320.62
Buy 12
Strong Buy 12
Buy 12
Strong Buy 12
Hold 7
Sell 1
Strong Sell 1
Strong Sell 1

ai summary icon Upturn AI SWOT

Alnylam Pharmaceuticals Inc

stock logo

Company Overview

overview logo History and Background

Alnylam Pharmaceuticals Inc. was founded in 2002 in Cambridge, MA. It pioneered RNA interference (RNAi) therapeutics, marking a significant advancement in treating genetic diseases. Key milestones include the FDA approval of Onpattro in 2018, the first RNAi therapeutic.

business area logo Core Business Areas

  • RNAi Therapeutics Development: Focuses on discovering, developing, and commercializing RNAi therapeutics for genetically defined diseases.
  • Commercialization: Markets and sells approved RNAi therapies globally.
  • Research and Development: Continues to invest in R&D to expand its pipeline of RNAi-based drugs.

leadership logo Leadership and Structure

The leadership team includes Yvonne Greenstreet, CEO. The organizational structure is based on functional departments (R&D, Commercial, Finance, etc.) and project-based teams focused on specific drug development programs.

Top Products and Market Share

overview logo Key Offerings

  • Onpattro (patisiran): Indicated for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy. 2023 revenue $647M. Competitors: Pfizer's Vyndaqel/Vyndamax, Ionis Pharmaceuticals' Tegsedi.
  • Givlaari (givosiran): Used to treat acute hepatic porphyria (AHP). 2023 revenue $224M. Competitors: No direct RNAi competitors, but treatments focus on managing symptoms.
  • Oxlumo (lumasiran): Treats primary hyperoxaluria type 1 (PH1). 2023 revenue $155M. Competitors: No direct RNAi competitors, primarily supportive care and liver/kidney transplantation.
  • Amvuttra (vutrisiran): Another RNAi therapeutic for hATTR amyloidosis with polyneuropathy, offering subcutaneous administration. Competitors: Onpattro (Alnylam) and Pfizer's Vyndaqel/Vyndamax, Ionis Pharmaceuticals' Tegsedi.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is highly competitive and R&D-intensive. RNAi therapeutics represent a novel class of drugs with potential for treating a wide range of diseases. Gene therapy and genetic medications market is rapidly growing.

Positioning

Alnylam is a leader in RNAi therapeutics, holding significant patents and expertise in the field. It has a first-mover advantage with several approved RNAi drugs.

Total Addressable Market (TAM)

The TAM for RNAi therapeutics is estimated to be in the billions of dollars, with continued expansion as more targets are identified and validated. Alnylam is well-positioned to capture a significant share of this market.

Upturn SWOT Analysis

Strengths

  • Pioneering RNAi technology
  • FDA-approved products
  • Strong patent portfolio
  • Experienced management team
  • Robust R&D pipeline

Weaknesses

  • High R&D costs
  • Reliance on single technology platform
  • Market access challenges (reimbursement)
  • Dependence on Key Products

Opportunities

  • Expansion of RNAi technology to new diseases
  • Partnerships with larger pharmaceutical companies
  • Acquisition of complementary technologies
  • Global market expansion
  • Positive clinical trial outcomes

Threats

  • Competition from other drug modalities
  • Patent challenges
  • Regulatory hurdles
  • Clinical trial failures
  • Economic downturn impacting healthcare spending

Competitors and Market Share

competitor logo Key Competitors

  • PFE
  • IONS

Competitive Landscape

Alnylam holds a leading position in RNAi therapeutics. However, competition is increasing as other companies develop alternative treatments for the same diseases. Alnylam's expertise and established platform give it a competitive edge.

Major Acquisitions

Sirna Therapeutics (partial assets)

  • Year: 2014
  • Acquisition Price (USD millions): 25
  • Strategic Rationale: Enhanced Alnylam's intellectual property and technology related to RNAi therapeutics.

Growth Trajectory and Initiatives

Historical Growth: Alnylam has experienced rapid revenue growth since the approval of its first product, Onpattro, in 2018.

Future Projections: Analysts project continued revenue growth driven by increased sales of existing products and the potential approval of new drugs in development. Expectations are that Amvuttra will out preform Onpattro in the future.

Recent Initiatives: Recent initiatives include expanding the indications for its existing drugs, advancing its pipeline of RNAi therapeutics, and exploring new delivery technologies.

Summary

Alnylam is a strong company at the forefront of RNAi therapeutics, with approved drugs driving significant revenue growth. Its robust pipeline and strong patent position provide a solid foundation for future growth. However, it faces challenges from competition, regulatory hurdles, and the high cost of R&D, but as the pioneer it has first movers advantages.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Alnylam Pharmaceuticals Inc. Investor Relations, SEC Filings, Analyst Reports

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may vary.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Alnylam Pharmaceuticals Inc

Exchange NASDAQ
Headquaters Cambridge, MA, United States
IPO Launch date 2004-05-28
CEO & Director Dr. Yvonne L. Greenstreet M.B.A., M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 2230
Full time employees 2230

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.